Company Overview of Allergan Inc.
Allergan, Inc. discovers, develops, and commercializes pharmaceuticals, biologics, medical, and over-the-counter products. It produces ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, and eyelash growth; and urology products. The company also provides medical devices such as breast implants for augmentation, revision, reconstructive surgery, and tissue expanders; and facial aesthetics products. Additionally, it researches and develops products in ophthalmology, neuromodulators, migraine, urology, medical dermatology, and medical aesthetics areas. The compa...
2525 Dupont Drive
Irvine, CA 92612
Founded in 1948
Key Executives for Allergan Inc.
Chairman and Chief Executive Officer
Chief Financial Officer and Executive Vice President of Finance & Business Development
Chief Scientific Officer and Executive Vice President of Research & Development
Principal Accounting Officer, Senior Vice President and Corporate Controller
Compensation as of Fiscal Year 2015.
Allergan Inc. Key Developments
Allergan Ceases Operations at its Generic Manufacturing and Packaging Facility in Iceland from 2016
Jul 3 15
Allergan announced that operations at its generic manufacturing and packaging facility in Iceland are to cease from 2016. The first phase of transferring manufacturing capacity to other production units will commence in the third quarter of 2016. According to a company statement, published on 29 June, the transition of manufacturing production to other sites, probably in Europe and Asia, is expected to be completed by mid-2017. However, Allergan's manufacturing site, which produces a reported 1.5 billion generic drugs per year, accounts for a large percentage of these export statistics. The decision to close the facility is therefore significant for the small, but domestically important, pharmaceutical sector.
Allergan Inc. Plans to Cut 577 Jobs at Irvine Headquarters
Apr 23 15
Allergan Inc. will lay off 577 workers from its Irvine headquarters effective June 4. In July 2014, the company announced it would shed 1,500 jobs, or 13% of its worldwide workforce, in an attempt to fend off a hostile $52 billion bid from Valeant Pharmaceuticals. This month's notice brings the total number of jobs cut since then to 1,491, nearly all in Irvine.
Parents of Melinda Ann Fortuna Files Suit against Allergan, Inc
Apr 10 15
Parents of Melinda Ann 'Mandy' Fortuna of Shelburne, Vermont filed suit against Allergan Inc., alleging that a series of off-label Botox overdoses were responsible for their daughter's death. Mandy Fortuna died in her sleep on September 25, 2014. An autopsy revealed no medical explanation for her death which was found to be as a result of 'atypical pneumonia'. Mandy Fortuna, who was diagnosed with cerebral palsy early in life, underwent a series of off-label Botox injections at the hands of Dr. Scott Benjamin of Burlington, Vermont. The last set of injections occurred on September 5, 2014, approximately three weeks prior to her death. In November 2014, two months after Mandy's death, the Fortuna's read in the Burlington Free Press that another child treated by Dr. Benjamin developed a seizure disorder following Botox injections. That earlier case went to trial in the United States District Court for the District of Vermont on November 3, 2014 and resulted in a $6.75 million verdict in favor of Joshua Drake and his family. The verdict in the Drake case included an award of $4 million in punitive damages against Allergan for outrageous conduct including illegal off-label promotion of Botox to treat children with cerebral palsy and associated muscle spasticity. The Fortuna's became suspicious about Mandy's unexplained deterioration in health and subsequent death after reading about the Drake verdict and realizing that Mandy had received Botox injections from the same doctor. After obtaining the injection records from Dr. Benjamin, the Fortuna's were able to confirm that Mandy Fortuna received an overdose of Botox, just like the child in the earlier case, Joshua Drake. The Fortuna's are represented by Ray Chester and the products liability team from McGinnis Lochridge, LLP in Austin, Texas. Mr. Chester and his team also represented the Drakes in the earlier Vermont lawsuit. In the Drake case, Chester brought forward evidence that Allergan sales representatives encouraged Dr. Benjamin to use high doses of off-label Botox on children, but then after Joshua Drake developed a seizure disorder, Allergan reported the event to the FDA as an overdose.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 17, 2014